TABLE 1.
Demographic and Clinical Characteristics at Enrollment and Follow-up
| Variables | p value |
|---|---|
| Enrollment | |
| Age, mean (range), y | 50 (22–87) |
| Women | 83% |
| Race | |
| Asian | 8% |
| Black | 10% |
| White | 82% |
| Latino | 13% |
| Diagnosis | |
| Systemic lupus erythematosus (SLE) | 28% |
| Rheumatoid arthritis (RA) | 27% |
| Undifferentiated connective tissue disorder (UCTD) | 8% |
| Psoriatic arthritis | 8% |
| Sjögren syndrome | 4% |
| Mixed connective tissue disorder | 3% |
| Othera | 22% |
| Medications for rheumatic diseaseb | |
| Conventional DMARDs | 84% |
| Biologic DMARDs | 55% |
| Follow-up | |
| Rheumatic disease activity during pandemic | |
| Typical | 36% |
| More active | 31% |
| Less active | 24% |
| Unpredictable | 9% |
| Current status of rheumatic disease | |
| Excellent | 10% |
| Very good | 22% |
| Good | 41% |
| Fair | 21% |
| Poor | 6% |
| How well coped psychologically during pandemic | |
| Very well | 30% |
| Well | 48% |
| Neutral | 15% |
| Fair | 4% |
| Poor | 3% |
a Spondyloarthritis 2%, SLE/UCTD overlap 2%, Sjögren/RA overlap 2%, polymyalgia rheumatica 2%, antiphospholipid syndrome/SLE 2%, ankylosing spondylitis 2%, granulomatosis with polyangiitis 1%, RA/SLE overlap 1%, RA/polymyalgia rheumatica overlap 1%, inflammatory polyarthralgia 1%, small vessel vasculitis 1%, scleroderma 1%, Churg-Strauss syndrome 1%, Still's disease 1%, atypical polyarteritis nodosa 1%, and eosinophilic granulomatosis with polyangiitis 1%.
b Forty-one percent taking both conventional and biologic DMARDs.